Safety of alternate-day treatment with TS-1TM (tegafur/gimeracil/oteracil) in tumor-bearing dogs: a pilot study
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 83 (8) , 1206-1211
Abstract
Tegafur is a prodrug of fluoropyrimidine 5-fluorouracil (5-FU), while TS-1TM is an oral fixed-dose combination of three active drugs, tegafur, gimeracil, and oteracil. This pilot study evaluated the safety of tegafur/gimeracil/oteracil in the treatment of cancers in dogs. Tegafur/gimeracil/oteracil was administered orally at a mean dose of 1.1 mg/kg twice daily on alternate days, Monday-Wednesday-Friday, every week to 11 dogs with tumors. Partial response and stable disease were observed in one dog each, whereas six exhibited progressive disease. Three dogs were not assessed. Adverse events, the most serious being grade 2, were noted in seven dogs. Adverse events were acceptable, and the drug was effective in some dogs. Therefore, tegafur/gimeracil/oteracil may be useful for treating malignant solid tumors in canines.Keywords
This publication has 20 references indexed in Scilit:
- Successful treatment of a dog with massive 5‐fluorouracil toxicosisJournal of Veterinary Emergency and Critical Care, 2013
- Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus documentVeterinary and Comparative Oncology, 2013
- Accidental and experimentally induced 5‐fluorouracil toxicity in dogsJournal of Veterinary Emergency and Critical Care, 2012
- The European Medicines Agency Review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the Treatment of Advanced Gastric Cancer When Given in Combination with Cisplatin: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use (CHMP)The Oncologist, 2011
- Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicityInternational Journal of Clinical Oncology, 2010
- Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future VistasJapanese Journal of Clinical Oncology, 2008
- Alternate-day oral therapy with TS-1 for advanced gastric cancerInternational Journal of Clinical Oncology, 2004
- A 52-WEEK ORAL TOXICITY STUDY OF A NEW ANTINEOPLASTIC AGENT S-1 IN DOGSThe Journal of Toxicological Sciences, 1996
- AN ORAL REPEATED DOSE TOXICITY STUDY OF A NEW ANTINEOPLASTIC AGENT S-1 IN DOGS : I. A 13-WEEK REPEATED DOSE TOXICITY STUDY, II. AN OPHTHALMOLOGIC TOXICITY RECOVERY STUDYThe Journal of Toxicological Sciences, 1996
- 5-Fluorouracil Toxicosis in the DogJournal of Veterinary Internal Medicine, 1990